CIK 0001764013
- Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 832771572
- Phone
- +1 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $895,852
- in 9 filings, $173K under 10b5-1 plans
Net −$895,852. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-22 | Barnett Eva Renee Chief Financial Officer | Sale | −2,930 | $36.15 | $106K | 320,420 |
| 2024-02-22 | Levine Mark S. Chief Legal Officer | Sale | −2,134 | $36.15 | $77K | 301,968 |
| 2024-02-22 | Macias William L. Chief Medical Officer | Sale | −2,221 | $36.15 | $80K | 330,952 |
| 2024-02-22 | Butchko Julia G. Chief Development Officer | Sale | −2,146 | $36.15 | $78K | 407,817 |
| 2024-02-22 | Salzmann Peter Chief Executive Officer | Sale | −13,454 | $36.15 | $486K | 931,231 |
| 2024-01-26 | Levine Mark S. Chief Legal Officer | Sale | −2,981 | $37.91 | $113K | 304,148 |
| 2024-01-26 | Levine Mark S. Chief Legal Officer | Sale | −46 | $38.45 | $2K | 304,102 |
| 2024-01-26 | Geffner Michael Chief Medical Officer | Sale | −9,948 | $37.91 | $377K | 90,052 |
| 2024-01-26 | Geffner Michael Chief Medical Officer | Sale | −153 | $38.45 | $6K | 89,899 |
| 2024-01-18 | Macias William L. Chief Medical Officer | Sale | −424 | $41.03 | $17K | 333,173 |
| 2024-01-11 | Barnett Eva Renee Chief Financial Officer | Sale | −2,681 | $41.64 | $112K | 324,184 |
| 2024-01-11 | Barnett Eva Renee Chief Financial Officer | Sale | −834 | $42.43 | $35K | 323,350 |
| 2024-01-05 | Butchko Julia G. Chief Development Officer | Sale | −1,297 | $38.59 | $50K | 409,963 |
| 2024-01-05 | Salzmann Peter Chief Executive Officer | Sale | −3,824 | $38.59 | $148K | 944,685 |
| 2023-12-01 | Fromkin Andrew J. Director | Sale 10b5-1 | −3,941 | $38.78 | $153K | 97,067 |
| 2023-12-01 | Fromkin Andrew J. Director | Sale 10b5-1 | −3,636 | $39.81 | $145K | 93,431 |
| 2023-12-01 | Fromkin Andrew J. Director | Sale 10b5-1 | −4,773 | $40.46 | $193K | 88,658 |
| 2023-12-01 | Pande Atul Director | Sale 10b5-1 | −4,129 | $38.80 | $160K | 91,379 |
| 2023-12-01 | Pande Atul Director | Sale 10b5-1 | −3,374 | $39.82 | $134K | 88,005 |
| 2023-12-01 | Pande Atul Director | Sale 10b5-1 | −4,847 | $40.46 | $196K | 83,158 |
Page 15 of 18 · 351 trades